Georgetown Lombardi Survivorship Research Initiative Seminar Series: “Cognitive Outcomes in Cancer Survivors: Predictors and Potential Interventions”
Noha Sharafeldin, MBBCh, MSc, PhD
Assistant Professor of Medicine, Division of Hematology & Oncology, University of Alabama at Birmingham School of Medicine
Member, Institute for Cancer Outcomes and Survivorship
Associate Scientist, O’Neal Comprehensive Cancer Center
presents
“Cognitive Outcomes in Cancer Survivors: Predictors and Potential Interventions”
Meet the Professor:
Dr. Sharafeldin will speak from 10 – 11 a.m. Immediately following the SRI seminar, there will be a 30-minute Meet the Professor session, which will provide attendees an opportunity to engage in Q&A and discuss specific research subjects with Dr. Sharafeldin.
This event is sponsored by the Georgetown Lombardi Survivorship Research Initiative, which works to optimize cancer survivorship across the lifespan and ensure equity for patients of every race, ethnicity, gender and socially determined status.
About the Speaker:
Dr. Sharafeldin is an assistant professor of medicine in the Division of Hematology & Oncology, University of Alabama at Birmingham (UAB), Institute for Cancer Outcomes and Survivorship, and O’Neal Comprehensive Cancer Center. She received training in medicine and an MSc of Public Health from Faculty of Medicine, Ain Shams University, Egypt; and a PhD in Clinical Epidemiology from University of Pierre and Marie Curie and in Public Health, specializing in genetic epidemiology, from University of Alberta, Canada. Her research program focuses on the study of genetic architecture of cancer and cancer outcomes, clinical, social, and genetic risk prediction to identify cancer survivors at risk for adverse outcomes including functional and cognitive outcomes, cardiotoxicity, and risk for second malignancies across the lifespan, as well as implementation of interventions to improve treatment-related outcomes in cancer survivors. She is PI on the cTAG and dcTAG studies (Diet and Cognitive Training and Attitudes towards Genetics): remote randomized controlled interventions to improve cognitive function in cancer survivors; and CAPITAL (Cognition in Advanced Prostate cancer patients treated with Androgen Blockers): a prospective cohort study to examine the rate of cognitive decline in patients receiving novel therapeutic agents. She co-leads the National Clinical Cohort Collaborative (N3C) Oncology Domain Team examining outcomes in cancer patients using the national N3C EMR-based resource. Her work has been supported by awards from the NCI, Leukemia & Lymphoma Society (LLS) and Be The Match Foundation. View her CV.